Figure 2.

Isavuconazole (ISA) + micafungin (MICA) combination therapy is not better than either drug alone in treating murine mucormycosis due to R. delemar. (a) Survival of neutropenic mice [n = 19 for placebo-, 18 for ISA- (given orally) (215 mg/kg three times daily), 19 for MICA- (administered by ip injection) and 13 for ISA + MICA-treated mice, from two separate experiments that included all treatment regimens] infected intratracheally with R. delemar (average inhaled inoculum of 1.3 × 10³ per mouse). Treatment started on day +1 and lasted through day +4, relative to infection. *P < 0.02 versus placebo-treated mice. (b) Lungs and brain fungal burden of mice (n = 10 per group) infected with R. delemar (average inoculum of 4.2 × 10³ per mouse), treated on days 0 (8 h post-infection) through +2 and sacrificed on day +3, relative to infection. Data are expressed as median ± IQR. *P < 0.03 versus placebo-treated mice and **P < 0.03 versus placebo- and MICA-treated mice.